PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Generalized anxiety disorder

Drugs in development · updated 30 October 2026

Generalized anxiety disorder: drugs in development

As of 30 October 2026 there are 19 active clinical trials (recruiting or ongoing, phases I–III) on 12 drugs for generalized anxiety disorder. 10 are experimental, that is not yet approved in the United States.

19Active trials
10Experimental drugs
5Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
BuagafuranIII3NCT06243614
ITI-1284III3NCT07807865
SEP-363856III3NCT07759128
DT120III2NCT06741228
JNJ-99245354III1NCT07856420
ABBV-932II1NCT06846320
CrisugabalinHSK16149II1NCT07330648
PsilocybinPsilocybineII1NCT06969170
RE104 for InjectionII1NCT07489651
SYT-510II1NCT07478744

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CannabidiolEpidiolex, Epidyolex®III2NCT07123467
BuspironeBuspar®III1NCT06243614

Sorted by most advanced phase and number of active trials.

All 12 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000098647 “Generalized Anxiety Disorder”.

ItalianoFrançaisDeutsch